Related content

Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease

By Guney Ibrahim   Selcuk N. Yilmaz   Altintepe Lutfullah   Atalay Huseyin   Başarali M. Kemal   Büyükbaş Sadik  

Renal Failure, Vol. 31, Iss. 9, 2009-10 ,pp. : 779-784

Informa Healthcare

Access to resources Recommend Favorite

Mineralocorticoid receptor activation as an etiological factor in kidney diseases

By Ueda Kohei   Nagase Miki  

Clinical and Experimental Nephrology, Vol. 18, Iss. 1, 2014-02 ,pp. : 16-23

Springer Publishing Company

Access to resources Recommend Favorite

Major Barriers against Renin–Angiotensin–Aldosterone System Blocker Use in Chronic Kidney Disease Stages 3–5 in Clinical Practice: A Safety Concern?

By Yildirim Tolga   Arici Mustafa   Piskinpasa Serhan   Aybal-Kutlugun Aysun   Yilmaz Rahmi   Altun Bulent   Erdem Yunus   Turgan Cetin  

Renal Failure, Vol. 34, Iss. 9, 2012-10 ,pp. : 1095-1099

Informa Healthcare

Access to resources Recommend Favorite

Does Renin-Angiotensin Aldosterone System Blockade Exacerbate Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease? A Prospective 50-month Mayo Clinic Study

By Onuigbo Macaulay   Onuigbo Nnonyelum  

Renal Failure, Vol. 30, Iss. 1, 2008-01 ,pp. : 67-72

Informa Healthcare

Access to resources Recommend Favorite

Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease

By Hamada Kazu   Taniguchi Yoshinori   Shimamura Yoshiko   Inoue Kosuke   Ogata Koji   Ishihara Masayuki   Horino Taro   Fujimoto Shimpei   Ohguro Takashi   Yoshimoto Yukio   Ikebe Mika   Yuasa Kenji   Hoshino Eri   Iiyama Tatsuo   Ichihara Atsuhiro   Terada Yoshio  

Clinical and Experimental Nephrology, Vol. 17, Iss. 6, 2013-12 ,pp. : 848-856

Springer Publishing Company

Access to resources Recommend Favorite